Acticor Biotech SAS (ALACT.PA)
5.58 €
-0.08 (-1.41%)
Rating:
Recommendation:
-
Symbol | ALACT.PA |
---|---|
Price | 5.58 € |
Beta | 0.000 |
Volume Avg. | 0.00M |
Market Cap | 68.643M |
Shares () | - |
52 Week Range | 5.1-11.0 |
1y Target Est | - |
DCF Unlevered | ALACT.PA DCF -> | |
---|---|---|
DCF Levered | ALACT.PA LDCF -> | |
ROE | - | |
ROA | - | |
Operating Margin | - | |
Debt / Equity | 162.61% | Buy |
P/E | -3.72 | Strong Sell |
P/B | 13.58 | Strong Buy |
About
Download (Excel)Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.